Lambert-Eaton News

November 5, 2020November 5, 2020

Rare Case of Lung Cancer-linked LEMS Underscores Importance of Screening

Lambert-Eaton News

A recent case study of a woman with Lambert-Eaton myasthenic syndrome (LEMS) linked to lung adenocarcinoma — a type of cancer of the mucus-producing gland cells in the lungs — ... Read more

October 30, 2020October 30, 2020

UK Organization ‘Same But Different’ Announces ‘Glimmer of Hope’ Photo Contest Winner

Lambert-Eaton News

A photo of a bespectacled young boy, his red baseball cap slightly askew as he  enjoys time outside, will be featured on the front cover of an upcoming calendar in ... Read more

October 29, 2020October 29, 2020

Firdapse Now Widely Available in Canada for Treating LEMS, KYE Pharmaceuticals Says

Lambert-Eaton News

Firdapse (amifampridine) is now widely available in Canada as a treatment for adults with Lambert-Eaton myasthenic syndrome (LEMS), according to KYE Pharmaceuticals, which markets the oral therapy. Health Canada, the ... Read more

October 23, 2020November 25, 2020

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

COVID-19 News, Lambert-Eaton News

A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a series ... Read more

October 22, 2020October 22, 2020

Catalyst Given US Patent Covering Firdapse in Treating LEMS

Lambert-Eaton News

The U.S. Patent and Trademark Office has issued a new patent to Catalyst Pharmaceuticals covering the company’s rights to Firdapse (amifampridine), a treatment for Lambert-Eaton myasthenic syndrome (LEMS). The patent (No. ... Read more

October 15, 2020October 15, 2020

NSF Funds Project to Make Better Computer Simulation of Nerve-muscle Communication

Lambert-Eaton News

A $750,000 grant from the National Science Foundation will fund a project to build a better computer model of the communication between nerves and muscle cells. The project may have ... Read more

October 8, 2020October 8, 2020

Newly Funded UNC Computer Simulations Could Help Find LEMS Treatments

Lambert-Eaton News

An $86,880 grant from the National Science Foundation will support the development of computer simulations that aim to improve scientists’ understanding of the neuromuscular junction (NMJ) — the site where ... Read more

October 7, 2020November 8, 2020

Same But Different Asks Public to Vote on ‘Glimmer of Hope’ Calendar Photos

COVID-19 News, Lambert-Eaton News

Same But Different, a nonprofit U.K. group that uses art for social change, is inviting people to choose their favorite photographs in a calendar contest to heighten awareness of rare diseases, ... Read more

October 1, 2020October 1, 2020

Ruzurgi Now Available in Canada for Patients Ages 6 or Older

Lambert-Eaton News

Ruzurgi (amifampridine), an oral treatment for Lambert-Eaton myasthenic syndrome (LEMS), is now available to Canadian patients ages 6 or older. Following its approval by Health Canada earlier this year, the ... Read more

October 1, 2020October 7, 2020

Ruzurgi Now Available in Canada for Patients Ages 6 or Older

Lambert-Eaton News

Ruzurgi (amifampridine), an oral treatment for Lambert-Eaton myasthenic syndrome (LEMS), is now available to Canadian patients ages 6 or older. Following its approval by Health Canada earlier this year, the ... Read more

September 10, 2020September 10, 2020

Wait Between Repeat Nerve Stimulation Tests in LEMS, Researcher Advises

Lambert-Eaton News

When monitoring Lambert-Eaton myasthenic syndrome (LEMS) patients, physicians should wait at least 150 seconds between nerve stimulation tests to avoid interference from prior exercise or electric stimulation in subsequent muscle ... Read more

September 10, 2020October 7, 2020

Wait Between Repeat Nerve Stimulation Tests in LEMS, Researcher Advises

Lambert-Eaton News

When monitoring Lambert-Eaton myasthenic syndrome (LEMS) patients, physicians should wait at least 150 seconds between nerve stimulation tests to avoid interference from prior exercise or electric stimulation in subsequent muscle ... Read more

August 27, 2020August 27, 2020

Catalyst, KYE Agree to Commercialize Firdapse for Adult LEMS Patients in Canada

Lambert-Eaton News

Catalyst Pharmaceuticals and KYE Pharmaceuticals have reached an exclusive agreement that will enable KYE to commercialize Firdapse (amifampridine), Catalyst’s oral therapy for adults with Lambert-Eaton myasthenic syndrome (LEMS), in Canada. The ... Read more

August 27, 2020October 7, 2020

Catalyst, KYE Agree to Commercialize Firdapse for Adult LEMS Patients in Canada

Lambert-Eaton News

Catalyst Pharmaceuticals and KYE Pharmaceuticals have reached an exclusive agreement that will enable KYE to commercialize Firdapse (amifampridine), Catalyst’s oral therapy for adults with Lambert-Eaton myasthenic syndrome (LEMS), in Canada. The ... Read more

August 25, 2020September 28, 2020

Xperiome Platform Aims to Streamline Searches for Rare Diseases, Gain Patient Input

Lambert-Eaton News

Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input ... Read more